Morphic announces corporate highlights and financial results for the first quarter 2024

Morf ends 1q24 with $659 million, cash into 2h27; phase 2b study of morf-057 in uc continues on target; anticipate garnet phase 2 in crohn's to begin 2q

MORF Ratings Summary

MORF Quant Ranking